A breakthrough pancreatic cancer drug won approval. They still struggle to access it

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-08T12:10:26.294Z • Permanent link

Regulatory bodies in the United States have given the green light to a groundbreaking pancreatic cancer treatment, marking a significant milestone in the ongoing quest for more effective treatments for the disease. The breakthrough, known as Zalutumumab, was developed by Incyte and Eli Lilly, two of the leading pharmaceutical companies in the world. Zalutumumab is the first fully human monoclonal antibody to target fibroblast growth factor receptors (FGFR) in the treatment of pancreatic cancer. According to data presented by Eli Lilly, Zalutumumab demonstrated a significant improvement in overall survival in patients with locally advanced or metastatic pancreatic cancer, with a median overall survival of 10.6 months compared to 6.7 months for the placebo group.

Zalutumumab has been in development since 2012, and its approval is the culmination of years of research and clinical trials. The drug has undergone rigorous testing, including phase I, II, and III trials, and has been reviewed by regulatory agencies in the United States and Europe. Dr. Mark Baselga, the former president of Lilly's oncology research and development, was instrumental in the development of Zalutumumab. Baselga, who is also a renowned oncologist, has been a driving force behind the development of several innovative cancer treatments.

Despite the significant progress made in the development of Zalutumumab, there are still concerns about access to the treatment. The high cost of the drug, combined with the limited availability of healthcare services in some parts of the country, may make it difficult for patients to access Zalutumumab. According to data from the Centers for Medicare and Medicaid Services, the average cost of Zalutumumab is around $150,000 per year, which is significantly higher than the average cost of other pancreatic cancer treatments.

Eli Lilly has announced plans to make Zalutumumab available to patients in the United States, but the company has also stated that it will not offer the treatment to patients who do not have access to a healthcare provider who is willing to prescribe the drug. This has raised concerns among patient advocacy groups, who are worried that the treatment will be inaccessible to many patients who need it most. The high cost of Zalutumumab is also a concern for researchers, who are worried that it will limit the availability of the treatment for patients who are willing to participate in clinical trials.

The approval of Zalutumumab also has significant implications for the broader oncology market. The approval of a new treatment for pancreatic cancer is a major milestone, and it is likely to have a significant impact on the sales of other treatments for the disease. According to data from the National Cancer Institute, pancreatic cancer is one of the most deadly forms of cancer in the world, with over 50,000 new cases diagnosed each year in the United States. The approval of Zalutumumab may provide new hope for patients who are struggling with this devastating disease.

The approval of Zalutumumab is part of a larger trend in the development of new cancer treatments. In recent years, there have been several breakthroughs in the development of innovative cancer treatments, including the approval of checkpoint inhibitors and targeted therapies. According to data from the National Cancer Institute, the development of these treatments has led to significant improvements in patient outcomes, including longer survival times and improved quality of life.